Featured News
Press Release
Strong Bipartisan Support for Continued Investment in Alzheimer’s Research on Full Display During Senate Appropriations Hearing
Senate appropriators from both sides of the aisle raise warnings of harm that would come from proposed research funding and staff cuts Washington, D.C., April 30, 2025 — During today’s Senate Appro...
All News
Press Release
Alzheimer’s Association Statement on European Medicines Agency Negative Opinion on Leqembi for the Treatment of Alzheimer’s Disease
CHICAGO, July 26, 2024 — The Alzheimer’s Association is disappointed by today’s decision by the European Medicines Agency (EMA) to...
AIM Blog
Recognizing AIM’s July Advocate of the Month: Molina Gonzales
Each month, we’re featuring an advocate who engages with policymakers to ensure priorities that improve the lives of people impacted...
Press Release
Alzheimer’s Association Welcomes U.S. FDA Approval of Kisunla (Donanemab)
CHICAGO, July 2, 2024 — The Alzheimer’s Association celebrates today’s U.S. Food and Drug Administration (FDA) action to approve Kisunla™...
AIM Blog
Congress Can Take Action During Alzheimer’s & Brain Awareness Month
The lifetime risk for Alzheimer's at age 45 is 1 in 5 for women and 1 in 10 for men...
AIM Blog
State Legislatures Take Action: Advancing Alzheimer’s Training for First Responders
Gloria Brown’s husband Arthur was diagnosed with Alzheimer’s in 2015. Two years later, while she was trying to get Arthur...
Press Release
Alzheimer’s Association Welcomes FDA Advisory Committee Unanimous Vote of Efficacy of Donanemab for the Treatment of Early Alzheimer’s Disease
CHICAGO, June 10, 2024 — The Alzheimer’s Association welcomes today’s U.S. Food and Drug Administration (FDA) advisory committee’s unanimous finding...